Sutro Biopharma Inc. (STRO) Appoints Heidi Hunter to its Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/15/2026
- S&P 500 and Nasdaq end higher on cool inflation data, solid bank earnings
- IBM plunges 19% as memory capex squeeze derails Q2 earnings
- Fed’s Warsh says central bank won’t tolerate high inflation
- Software stocks tumble: High memory prices cannibalize enterprise tech capex
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
- IBM misses Q2 targets as mainframe and software sales disappoint
- Verizon planning new round of layoffs this week - Barron’s
- S&P 500 and Nasdaq end higher on cool inflation data, solid bank earnings
- Lucid Group shares quickly cut in half on report of potential bankruptcy
- HSBC Downgrades IBM (IBM) to Reduce, 'Stretched Valuation'
Sutro Biopharma Announces Appointment of Heidi Hunter to Board of Directors
November 17, 2021 7:00 AM ESTSOUTH SAN FRANCISCO, Nov. 17, 2021 /PRNewswire/ --Â Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today announced that Heidi Hunter has been appointed to Sutro's Board of Directors.
"Heidi is an accomplished leader with considerable experience driving the successful development and commercialization of new medicines," said Bill Newell, Chief Executive Officer of Sutro. "We are delighted to have her join our Board as we continue to advance... More
